You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Dual View Endoscopy for Colonoscopy

    SBC: Omniscient Imaging, Inc.            Topic: 102

    AbstractAn estimatedmillion colonoscopies are performed annually in the US at a cost of about $Bhowever current colonoscopes with forward vision fail to detectof precancerous polypsOverof the missed polyps are located on or behind numerous folds in the colon where they are hidden from the sight of a forward view colonoscopeIn this research proposalwe propose to complete our development of an imagi ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Application of PPODA-QT for embolization of aneurysms

    SBC: ANEUVAS TECHNOLOGIES INC            Topic: 101

    PROJECT SUMMARY/ABSTRACTA cerebral aneurysm is an abnormal enlargement or pouch that forms from a weakened vessel segment in the brain. Often going unnoticed and untreated, an aneurysm can cause a sudden and catastrophic hemorrhage or stroke. Approximately 15 % of patients die from an aneurysm rupture even before receiving medical attention and 25 % of patients die despite medical treatment. Patie ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Aminoglycosides with reduced ototoxicity via miRNA targeting

    SBC: NUBAD LLC            Topic: NIAID

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low cost methods to develop aminoglycosides with anti- ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced o ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Glioblastoma multiforme therapy via telomerase reverse transcriptase (hTERT) down-regulation. Molecular chaperones redirect quadruplex folding to reverse the effect of hTERT gene promoter mutations.

    SBC: Reglagene, LLC            Topic: 106

    Project Summary Overexpression of hTERT is a hallmark of cancer and is associated with oncogenesistumor maintenanceand resistance to conventional chemotherapyElongated telomeres at the ends of chromosomes are a hallmark for cancer in the early stage of tumorigenesis and are associated with genetic instabilityAs a consequencesuppressed telomerase in normal cells is highly activated to immortalize t ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Discovery of T-type Calcium Channel Antagonists from Multicomponent Reactions and Their Application in Paclitaxel-induced Peripheral Neuropathy

    SBC: Regulonix            Topic: 101

    Summary Abstract Chemotherapy induced peripheral neuropathyCIPNis detected inof cancer patients during all phases of cancerSensory symptoms in the hands and or feettypically in astocking glovepatternare commonand manifested as painnumbnessand or tinglingCIPN can result in chemotherapy dose reduction or discontinuationand can also have long term effects on the quality of lifeThe course of CIPN can ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil

    SBC: AcePre, LLC            Topic: NCCIH

    PROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. DNA Quadruplex Control of hTERT Transcription: A New Therapy for Taxotere Resistant Prostate Cancer

    SBC: Reglagene, LLC            Topic: 102

    PROJECT SUMMARYTelomerase maintains telomere length and prevents cellular senescenceIt is upregulated inof cancerssuppressed in most non cancer tissuesand is a primary driver of tumor cell immortalityNo clinical agent acting on telomerase has been approved for human useA hurdle for approaches that directly inhibit the action of telomerase is that therapeutic effect is observed only after many popu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government